The DOI matches its Crossref record.
Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants
Abstract
BACKGROUND: Rotavirus gastroenteritis, a major cause of mortality and morbidity worldwide, is a vaccine-preventable disease. New safe and effective candidate rotavirus vaccines are needed to replace the withdrawn rhesus rotavirus-based oral vaccine. METHODS: We evaluated a monovalent human rotavirus vaccine, serotype G1, strain RIX4414, for efficacy, immunogenicity and safety in a randomized, double blind, placebo-controlled trial in Finland. We randomly allocated 405 healthy infants to receive 2 doses of vaccine or placebo (ratio 2:1) at approximately 2 and 4 months of age. The infants were followed during 2 rotavirus epidemic seasons (2000-2002) for acute gastroenteritis. Rotaviruses in diarrheal stool samples were primarily detected by enzyme-linked immunosorbent assay and confirmed and G-typed by reverse transciption-polymerase chain reaction. RESULTS: The vaccine was well-tolerated. No vaccine-related serious adverse events were observed during the study period. Rotavirus IgA (enzyme-linked immunosorbent assay) seroconversion rate was 80% after 2 doses. Thirty-eight cases of rotavirus gastroenteritis were detected during the entire follow-up period; 35 of these were of the G1 type. RIX4414 vaccine significantly decreased the occurrence of any rotavirus compared with placebo. Efficacy during the first rotavirus epidemic season was 73% [95% confidence interval (95% CI), 27-91%] and 90% (95% CI 10-100%) against any and severe rotavirus gastroenteritis, respectively, and during the entire follow-up period 72% (95% CI 42-87%) against any and 85% (95% CI 42-97%) against severe rotavirus gastroenteritis (P < 0.05 for all comparisons). CONCLUSIONS: RIX4414 strain of G1 human rotavirus vaccine was well-tolerated, immunogenic and efficacious in infants against rotavirus gastroenteritis during a 2-year period. To further increase vaccine "take" and efficacy, a higher dose of this vaccine may be considered for future efficacy trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Ruiz-Palacios, G. M., Pérez-Schael, I., Velázquez, F. R., Abate, H., Breuer, T., Clemens, S. C., Cheuvart, B., Espinoza, F., Gillard, P., Innis, B. L., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052434 · Cited by 1,799
Self-citationVesikari, T., Karvonen, A., Prymula, R., Schuster, V, Tejedor, J., Cohen, R., Meurice, F., Han, H., Damaso, S., & Bouckenooghe, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61744-9 · Cited by 636
Self-citationRotavirus vaccines: current prospects and future challenges
Glass, R. I., Parashar, U. D., Bresee, J. S., Turcios, R., Fischer, T. K., Widdowson, M.-A., Jiang, B., & Gentsch, J. R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68815-6 · Cited by 482
Vaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub3 · Cited by 381
Burden of Rotavirus Disease in European Union Countries
Soriano-Gabarró, M., Mrukowicz, J., Vesikari, T., & Verstraeten, T. (2006) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000197622.98559.01 · Cited by 336
Self-citation
Metadata
- Authors
- Vesikari, T., Karvonen, A., Puustinen, L., Zeng, S.-Q., Szakal, E. D., Delem, A., & De Vos, B.
- Venue
- Pediatric Infectious Disease Journal
- Published
- 2004-10
- Volume
- 23
- Issue
- 10
- Pages
- 937-943
- ISSN
- 0891-3668 (ISSN-L)
- OpenAlex
- W1966417805
- Cited by
- 214
- References
- 0
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants. https://app.cochat.ai/papers/10.1097/01.inf.0000141722.10130.50
- The paper
- Vesikari, T., Karvonen, A., Puustinen, L., Zeng, S.-Q., Szakal, E. D., Delem, A., & De Vos, B. (2004). Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants. Pediatric Infectious Disease Journal. https://doi.org/10.1097/01.inf.0000141722.10130.50
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.